| Title |
Risk of venous thromboembolism following influenza vaccination in adults aged 50years and older in the Vaccine Safety Datalink
|
|---|---|
| Published in |
Vaccine, September 2017
|
| DOI | 10.1016/j.vaccine.2017.08.086 |
| Pubmed ID | |
| Authors |
Elizabeth R. Vickers, David L. McClure, Allison L. Naleway, Steven J. Jacobsen, Nicola P. Klein, Jason M. Glanz, Eric S. Weintraub, Edward A. Belongia |
| Abstract |
Influenza-like illness and inflammation are known risk factors for venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). However, few studies have characterized the risk of VTE following influenza vaccination. We examined VTE risk after vaccination in adults 50years old and older within the Vaccine Safety Datalink (VSD). We used the self-controlled case series method to determine the risk of VTE among age-eligible adults who received influenza vaccine (with or without pandemic H1N1) and experienced a VTE during the months of September through December in 2007 through 2012. Presumptive VTE cases were identified among VSD participants using diagnostic codes, diagnostic tests, and oral anticoagulant prescription. Potential cases were validated by medical record review. The VTE incidence rate ratio was calculated among confirmed cases for the risk window 1 to 10days after vaccination relative to all other person-time from September through December. Of the 1,488 presumptive cases identified, 508 were reviewed, of which 492 (97%) were confirmed cases of VTE. The analysis included 396 incident, confirmed cases. Overall, there was no increased risk of VTE in the 1 to 10days after influenza vaccination (IRR=0.89, 95% CI 0.69-1.17) compared to the control period. Results were similar when all person-time was censored before vaccination. A post hoc analysis showed an increased risk among current tobacco smokers (IRR=2.57, 95% CI 1.06-6.23). No clustering of VTE was observed in the 1-42days after vaccination. Overall, there was no evidence that inactivated influenza vaccine was associated with VTE in adults ≥50years old. An increased risk was found among current smokers in a post hoc analysis. These findings are consistent with previous research and support the safety of annual vaccination in this population. |
X Demographics
The data shown below were collected from the profiles of 29 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 4 | 14% |
| United States | 4 | 14% |
| Australia | 2 | 7% |
| Poland | 1 | 3% |
| Canada | 1 | 3% |
| Japan | 1 | 3% |
| Unknown | 16 | 55% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 26 | 90% |
| Scientists | 2 | 7% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 32 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 16% |
| Student > Bachelor | 4 | 13% |
| Researcher | 4 | 13% |
| Other | 3 | 9% |
| Student > Master | 3 | 9% |
| Other | 4 | 13% |
| Unknown | 9 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 38% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Arts and Humanities | 2 | 6% |
| Agricultural and Biological Sciences | 2 | 6% |
| Mathematics | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 10 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 153. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 March 2024.
All research outputs
#275,021
of 25,789,020 outputs
Outputs from Vaccine
#264
of 16,629 outputs
Outputs of similar age
#5,764
of 324,369 outputs
Outputs of similar age from Vaccine
#7
of 212 outputs
Altmetric has tracked 25,789,020 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,629 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.9. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,369 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 212 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.